Sheldon L. Holder, MD, PhD, is a Physician Scientist in the Cancer Center at Brown University. He is an Assistant Professor in the Department of Pathology and Laboratory Medicine at Brown University and an Attending Physician in the Division of Hematology/Oncology at the Lifespan Cancer Institute.
Dr. Holder obtained his Bachelor of Science degree from Oakwood University and his MD/PhD degrees from Loma Linda University (PhD in Microbiology and Molecular Genetics with Dr. Michael Lilly). He completed Internal Medicine Residency training at the Penn State Milton S. Hershey Medical Center and Hematology/Oncology Fellowship training at the Vanderbilt-Ingram Comprehensive Cancer Center.
Dr. Holder maintains an active research laboratory where he studies novel targets for cancer therapy, with a particular focus on PIM1 Kinase as a therapeutic cancer target. He also maintains an active oncology clinic where he treats patients with genito-urinary malignancies.
| Joshi M, Holder SL, Zhu J, Zheng H, Komanduri S, Warrick J, Yasin H, Garje R, Jia B, Drabick JJ, DeGraff DJ, Zakharia Y. "Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study." European urology focus, 2021. |
| Joshi M, Grivas P, Mortazavi A, Monk P, Clinton SK, Sue-Ann Woo M, Holder SL, Drabick JJ, Yin M. "Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer." Cancer medicine, vol. 9, no. 24, 2020, pp. 9365-9372. |
| Yin M, Grivas P, Wang QE, Mortazavi A, Emamekhoo H, Holder SL, Drabick JJ, Woo MS, Pal S, Vasekar M, Folefac E, Clinton SK, Monk P, Joshi M. "Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer." The oncologist, vol. 25, no. 8, 2020, pp. 680-688. |
| Wang M, Chi G, Bodovski Y, Holder SL, Lengerich EJ, Wasserman E, McDonald AC. "Temporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancer." Cancer Causes & Control, vol. 31, no. 1, 2020, pp. 63-71. |
| Zaleski M, Gogoj A, Walter V, Raman JD, Kaag M, Merrill SB, Drabick J, Joshi M, Holder S, DeGraff DJ, Warrick JI. "Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system." Human Pathology, vol. 84, 2019, pp. 275-282. |
| Joshi M, Warrick JI, Yin M, Holder SL, Drabick JJ. "Need for a personalized approach for muscle invasive bladder cancer: role of tumor biology in response to neoadjuvant chemotherapy." Translational andrology and urology, vol. 8, no. Suppl 1, 2019, pp. S99-S103. |
| Joshi M, Millis SZ, Arguello D, Holder SL, Lamm D, Reddy S, Belani C, Drabick JJ, Vogelzang NJ. "Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers." European urology focus, vol. 4, no. 1, 2018, pp. 94-97. |
| Small J, Washburn E, Millington K, Zhu J, Holder SL. "The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors." Oncotarget, vol. 8, no. 56, 2017, pp. 95116-95134. |
| Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, Harouaka R, Zheng SY, Drabick JJ, Lamparella NE, Truica CI, El-Deiry WS. "A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells." Oncotarget, vol. 7, no. 4, 2016, pp. 3662-76. |
| Al-Marrawi MY, Mackley HB, Ali S, Wagner H, Joshi M, Holder S, Kaag M, Mallon C, Talamo G, Drabick JJ. "Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review." Clinical genitourinary cancer, vol. 14, no. 4, 2016, pp. e393-9. |
| Al-Marrawi MY, Holder SL. "Current Immunotherapies for Renal Cell Carcinoma." Current molecular pharmacology, vol. 9, no. 3, 2016, pp. 252-263. |
| Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ. "Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis." The oncologist, vol. 21, no. 6, 2016, pp. 708-15. |
| Joshi M, Vasekar M, Grivas P, Emamekhoo H, Hsu J, Miller VA, Stephens PJ, Ali SM, Ross JS, Zhu J, Warrick J, Drabick JJ, Holder SL, Kaag M, Li M, Pal SK. "Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma." Oncotarget, vol. 7, no. 32, 2016, pp. 52442-52449. |
| Yin M, Wang W, Rosenberg J, Kaag M, Joshi M, Holder S, Tuanquin L, Drabick JJ. "Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review." Clinical genitourinary cancer, vol. 14, no. 2, 2016, pp. e203-6. |
| Holder SL, Drabick J, Zhu J, Joshi M. "Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer." Cancer Biology & Therapy, vol. 16, no. 2, 2015, pp. 207-9. |
| Al-Marrawi MY, Cream LV, Mallon CA, Holder S, Joshi M, Harvey HH, Talamo G, Drabick JJ. "Effect of topical vaginal androgens in a woman on the testosterone levels of her sexual partner with prostate cancer." Journal of Clinical Oncology, vol. 33, no. 5, 2015, pp. 521-2. |
| Wang W, Cheng J, Mallon C, Al-Marrawi MY, Holder S, Joshi M, Kaag M, Talamo G, Drabick JJ. "Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review." Clinical genitourinary cancer, vol. 13, no. 6, 2015, pp. e391-5. |
| Lipkin JS, Rizvi SM, Gatalica Z, Sarwani NE, Holder SL, Kaag M, Drabick JJ, Joshi M. "Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression." Cancer Biology & Therapy, vol. 16, no. 1, 2015, pp. 28-33. |
| Holder SL, Abdulkadir SA. "PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance." Current cancer drug targets, vol. 14, no. 2, 2014, pp. 105-14. |
| Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. "Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase." Molecular Cancer Therapeutics, vol. 6, no. 1, 2007, pp. 163-72. |
| Holder S, Lilly M, Brown ML. "Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase." Bioorganic & Medicinal Chemistry, vol. 15, no. 19, 2007, pp. 6463-73. |
Invited talks:
| Year | Degree | Institution |
|---|---|---|
| 2007 | PhD | Loma Linda University |
| 2007 | MD | Loma Linda University |
| Hematology/Oncology | Vanderbilt Ingram Cancer Center, hematology/oncology | 2013-2013 | |
| Internal Medicine | Penn State M. S. Hershey Medical Center, internal medicine | 2010-2010 | |
| MD | Loma Linda University | 2007- | |
| PhD - Microbiology and Molecular Genetics | Loma Linda University | 2005- | |
| B.Sc. | Oakwood University, Biological Sciences | 1998- |
| Name | Title |
|---|---|
| El-Deiry, Wafik | Mencoff Family University Professor of Medical Science, Professor of Pathology and Laboratory Medicine |
Warren Alpert Medical School
Cancer Center at Brown University
Department of Pathology and Laboratory Medicine
Lifespan Cancer Institute
